Posters –
Immunology and Oncology
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
PREDMED
Virginie MIATH
SATT CONECTUS ALSACE
Decision tool for personalised medicine in oncology
Prediction of the efficacy of marketed or experimental therapeutic strategies acting on
different kind of targets (angiogenesis, migration, repair...)
Technology
The signatures are robust as attested by the validation procedures, either in terms of
precision, stability, sensitivity and reactivity
Conclusive preliminary clinical evaluation (retrospective study): the score is predictive of
the patient outcome
POC: glioblastoma, colon and prostate cancer
Customers / Target market
Industry and competitors
This tool provides clinicians with information that allows them to individualize and
optimize the regimen of the patient. Our test have a larger applications than usual
"companion diagnostic test" (single drug oriented), since the clinician retains the initiative
in the choice of treatment among the armamentarium available. In addition to the
diagnostic companies that are able to develop and commercialize this type of tests
through specialized services facilities, we also prospect pharmaceutical companies
wishing to refine the stratification of patients in clinical development of their therapeutic
molecules or use our invention as theranostic test for the development of new drugs
based on the inhibition of targets analyzed in our test.
The global market for molecular diagnostics in oncology is evolving very quickly and is a
boon for the pharmaceutical industry and companies specialized in the marketing of
diagnostic tools with considerable economic potential. These techniques are also highly
valued by the health authorities in the context rationalization of the therapeutic
management of patients and optimization of the benefit/risk ratio.
The growth rate of molecular diagnostics in oncology market is about 31.4% CAGR. The
molecular diagnostics market applied to oncology in the U.S. alone is reached neatly USD
1.83 billion in 2014.
Financing need / Commercial
opportunity
IP – Patent situation
Licensing
2 patents being written so as to protect 2 applications of the score:
1. Determination of the best therapeutic strategy for a given patient
2. Efficacy of a given treatment according to its score with respect to a definite threshold.
Future steps / Milestones
N/A
Further reading
N/A
Contact person
Virginie MIATH, Project Manager, SATT CONECTUS ALSACE,
virginie.miath@satt.conectus.fr